Vos, JM;
Notermans, NC;
D'Sa, S;
Lunn, MP;
van der Pol, WL;
Kraan, W;
Reilly, MM;
... Minnema, MC; + view all
(2017)
High prevalence of the MYD88 L265P mutation in IgM anti-MAG paraprotein-associated peripheral neuropathy.
[Letter].
Journal of Neurology, Neurosurgery & Psychiatry
, 89
(9)
pp. 1007-1009.
10.1136/jnnp-2017-316689.
Preview |
Text
Lunn_High prevalence of the MYD88 L265P mutation in IgM anti-MAG paraprotein-associated peripheral neuropathy_AAM.pdf - Accepted Version Download (156kB) | Preview |
Abstract
Immunoglobulin M (IgM) anti-myelin-associated glycoprotein (MAG) paraprotein-associated peripheral neuropathy (anti-MAG PN) is the most frequent type of paraprotein-associated neuropathy. It typically presents as a chronic demyelinating disorder with progressive ataxia, tremor and sensory disturbance.1 By definition, IgM paraproteinaemia and high-titre anti-MAG antibodies are present. Up to 50% of patients develop significant disability. Progressive disease-related disability is considered an indication to start treatment. However, there is no consensus on the optimal treatment approach and a high clinical need for effective therapies.
Archive Staff Only
 |
View Item |
